GuidelineESMO open2024
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.
Guideline in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Development of a Nomogram-Based Clinical Estimation Model for Pathological Upstaging in Patients With Preoperative Ductal Carcinoma In Situ.The Kaohsiung journal of medical sciences · 2026Article
- The Burden of Breast Cancer and its Attributable Risk Factors in 204 Countries and Territories, 1990-2021: Results From the Global Burden of Disease Study 2021.Cancer innovation · 2026Article
- Identification and Localization of Breast Tumor Components via a Convolutional Neural Network Based on High-Frequency Ultrasound Combined With Histopathologic Registration: Prospective Study.JMIR medical informatics · 2026Article
- Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Concurrent human epidermal growth factor receptor 2-positive breast cancer with axillary nodal metastasis in a patient with pituitary prolactinoma: a case report.AME case reports · 2026Article
- Review
- The Early Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients with Early Breast Cancer.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Decoding Breast Cancer: Emerging Molecular Biomarkers and Novel Therapeutic Targets for Precision Medicine.International journal of molecular sciences · 2025Review
- Real-World Epidemiology, Clinical Characteristics and Outcomes of Women with Germline BRCA Mutation and Early Breast Cancer in China.Oncology and therapy · 2025Article
- Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations.Discover oncology · 2025Review
- Article
- Article
- Advances in hydrogel-based materials for breast cancer bone metastasis: from targeted drug delivery to bone microenvironment remodeling.Frontiers in pharmacology · 2025Review
- PET imaging of CXCR4 expression using [Theranostics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer were updated and published online in 2023, and adapted, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with early breast cancer. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with breast cancer representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and KSMO. The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with early breast cancer across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling, as well as the age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.